Using data from 2 million claims across 32 states, the study found that the prevalence of these surgeries increased, driven by shoulder joint replacements.
While AI can be effective in some elements of drug design, AI models currently struggle to explain their decision making, a key component of drug review.
After regional public health collaboratives formed in September, New York could be the first state to formally shift policies away from deferring to federal guidelines.